向瘤血管:从血管破坏到促进
Sophie Guelfi1, Kairbaan Hodivala-Dilke2, Gabriele Bergers3
1Department of Oncology, VIB-KU Leuven Center for Cancer Biology and KU Leuven, Leuven, Belgium.
Nature reviews. Cancer
|August 29, 2024
概括
通过血管生成策略向瘤血管系统在癌症治疗中显示出有前途. 不同的方法,包括正常化和免疫治疗的双重向,改善了结果,但根据癌症类型而异.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 瘤微环境 瘤微环境
背景情况:
- 血管新生对于瘤生长和生存至关重要.
- 血管向策略旨在抑制或修改瘤血管结构.
- 目前的成功仅限于特定的癌症类型.
研究的目的:
- 在癌症治疗中审查各种血管向策略.
- 根据瘤血管在瘤微环境中的作用来对这些方法进行背景化.
- 探索改善癌症治疗的未来方向.
主要方法:
- 血管新生和血管向策略的文献综述.
- 分析瘤血管和微观环境之间的功能联系.
- 讨论双重向方法和未来的治疗途径.
主要成果:
- 存在各种策略,包括血管生长抑制,破坏,正常化,重编程和促进.
- 一些策略与标准护理相结合,可以改善癌症疗法,但有效性取决于癌症类型.
- 了解瘤血管作为瘤微环境的一部分是关键.
结论:
- 血管向策略已经显著发展.
- 血管和免疫细胞的双重向显示出有希望的结果.
- 未来的研究应该探索新型癌症疗法的血管系统和其他微环境组件之间的联系.
更多相关视频
12:09A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics
Published on: June 16, 2013
11.5K
04:00A Matrigel-Based Tube Formation Assay to Assess the Vasculogenic Activity of Tumor Cells
Published on: September 7, 2011
66.2K
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Mechanism of Angiogenesis
5.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.4K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
